Anagenics (ASX:AN1) - Share price, News & Analysis

AN1 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

AN1 Stock Overview

Anagenics Limited, a consumer health company, develops, manufactures, and markets anti-aging products for hair, skin, and wellbeing in Australia, the United States, China, and Japan.

Rewards

Earnings have grown 0.1% per year over the past 5 years

Risk Analysis

Does not have a meaningful market cap (A$4M)

Shareholders have been diluted in the past year

Anagenics Competitors

Bioxyne

ASX:BXN

AU$7.0m

Holista Colltech

ASX:HCT

AU$8.0m

Biome Australia

ASX:BIO

AU$16.4m

Elixinol Wellness

ASX:EXL

AU$6.6m

Price History & Performance

Summary of all time highs, changes and price drops for Anagenics
Historical stock prices
Current Share Price	AU$0.021
52 Week High	AU$0.073
52 Week Low	AU$0.019
Beta	-1.17
1 Month Change	-40.00%
3 Month Change	-53.33%
1 Year Change	-65.00%
3 Year Change	-88.65%
5 Year Change	-95.80%
Change since IPO	-99.46%

Shareholder Returns

	AN1	AU Personal Products	AU Market
7D	-16.0%	-1.6%	2.8%
1Y	-65.0%	-33.6%	-9.6%

Return vs Industry: AN1 underperformed the Australian Personal Products industry which returned -33.6% over the past year.

Return vs Market: AN1 underperformed the Australian Market which returned -9.6% over the past year.

Price Volatility

Is AN1's price volatile compared to industry and market?
AN1 volatility
AN1 Average Weekly Movement	12.6%
Personal Products Industry Average Movement	9.3%
Market Average Movement	9.8%
10% most volatile stocks in AU Market	16.5%
10% least volatile stocks in AU Market	4.3%

Stable Share Price: AN1 is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: AN1's weekly volatility (13%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2004	n/a	Matthew Dudek	https://www.anagenics.com

Anagenics Limited, a consumer health company, develops, manufactures, and markets anti-aging products for hair, skin, and wellbeing in Australia, the United States, China, and Japan. It develops and sales FGF5 inhibitor hair health and hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. In addition, the company markets its products through retailers and wholesalers, as well as through a direct-to-consumer, e-commerce platform.

Anagenics Fundamentals Summary

How do Anagenics's earnings and revenue compare to its market cap?
AN1 fundamental statistics
Market Cap	AU$4.20m
Earnings (TTM)	-AU$3.28m
Revenue (TTM)	AU$7.20m

0.6x

P/S Ratio

-1.4x

P/E Ratio

Is AN1 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
AN1 income statement (TTM)
Revenue	AU$7.20m
Cost of Revenue	AU$2.95m
Gross Profit	AU$4.25m
Other Expenses	AU$7.53m
Earnings	-AU$3.28m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.015
Gross Margin	58.99%
Net Profit Margin	-45.53%
Debt/Equity Ratio	15.9%

How did AN1 perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is AN1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AN1?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for AN1. This is calculated by dividing AN1's market cap by their current preferred multiple.
What is AN1's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	AU$4.20m

AN1 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.2x
Enterprise Value/EBITDA	-0.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does AN1's PS Ratio compare to its peers?

AN1 PS Ratio vs Peers

The above table shows the PS ratio for AN1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	2.4x
BXN Bioxyne	3x	n/a	AU$7.0m
HCT Holista Colltech	1.2x	n/a	AU$8.0m
BIO Biome Australia	4.7x	46.8%	AU$16.4m
EXL Elixinol Wellness	0.7x	n/a	AU$6.6m
AN1 Anagenics	0.6x	n/a	AU$4.2m

Forward PS

Price-To-Sales vs Peers: AN1 is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (2.4x).

Price to Earnings Ratio vs Industry

How does AN1's PE Ratio compare vs other companies in the Global Personal Products Industry?

Price-To-Sales vs Industry: AN1 is good value based on its Price-To-Sales Ratio (0.6x) compared to the Global Personal Products industry average (1.8x)

Price to Sales Ratio vs Fair Ratio

What is AN1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AN1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.6x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate AN1's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of AN1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AN1's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AN1's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AN1's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Anagenics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

29.8%

Forecasted Household industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Anagenics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Examine Anagenics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
Anagenics competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Anagenics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

0.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AN1 is currently unprofitable.

Growing Profit Margin: AN1 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: AN1 is unprofitable, but has reduced losses over the past 5 years at a rate of 0.1% per year.

Accelerating Growth: Unable to compare AN1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AN1 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (14.3%).

Return on Equity

High ROE: AN1 has a negative Return on Equity (-30.65%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Anagenics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AN1's short term assets (A$11.4M) exceed its short term liabilities (A$5.0M).

Long Term Liabilities: AN1's short term assets (A$11.4M) exceed its long term liabilities (A$1.4M).

Debt to Equity History and Analysis

Debt Level: AN1 has more cash than its total debt.

Reducing Debt: AN1's debt to equity ratio has reduced from 17.1% to 15.9% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AN1 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AN1 has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 3.9% each year.

Discover healthy companies

Dividend

What is Anagenics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate AN1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AN1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AN1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AN1's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AN1 has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure

CEO

Matthew Dudek

0.33

Tenure

Mr. Matthew Dudek serves as Acting Chief Executive Officer at Anagenics Limited (formerly known as Cellmid Limited) since February 28, 2022 and served as its Group Financial Controller since March 2021 unt...

Leadership Team

Experienced Management: AN1's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.9%.

Data	Last Updated (UTC time)
Company Analysis	2022/06/28 00:00
End of Day Share Price	2022/06/28 00:00
Earnings	2021/12/31
Annual Earnings	2021/06/30